Evaxion Biotech AS Cash Flow Conversion Efficiency
Evaxion Biotech AS cash flow conversion efficiency. Based on the latest financial reports, Evaxion Biotech AS (EVAX) has a cash flow conversion efficiency ratio of -0.390x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.65 Million) by net assets ($17.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Evaxion Biotech AS (2018–2025)
Cash flow conversion efficiency of Evaxion Biotech AS from 2018 to 2025. This chart illustrates how Evaxion Biotech AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Evaxion Biotech AS for real-time trading data and today's change.
Evaxion Biotech AS Cash Flow Conversion Ratio Explained
Evaxion Biotech AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Evaxion Biotech AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evaxion Biotech AS ranked by their cash flow conversion efficiency. Also see EVAX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanatana Resources
V:STA
|
-0.300x |
|
CPI Aerostructures Inc
NYSE:CVU
|
0.008x |
|
TOP Engineering Co. Ltd
KQ:065130
|
0.098x |
|
Galva Technologies Tbk PT
JK:GLVA
|
0.582x |
|
Nexam Chemical Holding AB
ST:NEXAM
|
-0.024x |
|
Baylin Technologies Inc
TO:BYL
|
-0.042x |
|
Romcarbon Sa B
RO:ROCE
|
-0.041x |
|
Megachem (Thailand) Public Company Limited
BK:MGT
|
0.034x |
Annual Cash Flow Conversion Efficiency for Evaxion Biotech AS (2018–2025)
The table below shows the annual cash flow conversion efficiency of Evaxion Biotech AS from 2018 to 2025. Review EVAX free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-6.65 Million | -0.390x | -104.98% |
| 2024-12-31 | $-1.65 Million | $-12.94 Million | 7.833x | +109.38% |
| 2023-12-31 | $-4.73 Million | $-17.69 Million | 3.741x | +220.51% |
| 2022-12-31 | $8.30 Million | $-25.77 Million | -3.104x | -359.08% |
| 2021-12-31 | $32.44 Million | $-21.93 Million | -0.676x | +61.74% |
| 2020-12-31 | $7.04 Million | $-12.44 Million | -1.767x | -135.48% |
| 2019-12-31 | $9.36 Million | $-7.03 Million | -0.750x | -135.09% |
| 2018-12-31 | $-931.00K | $-1.99 Million | 2.139x | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more